Intestinal Decontamination Therapy for Dyskinesia and Motor Fluctuations in Parkinson's Disease

Parkinson's disease is neurodegenerative disorder with an initial robust response to levodopa. As the disease progresses, patients frequently develop dyskinesia and motor fluctuations, which are sometimes resistant to pharmacological therapy. In recent years, abnormalities in gut microbiota hav...

Full description

Bibliographic Details
Main Authors: José Fidel Baizabal-Carvallo, Marlene Alonso-Juarez, Robert Fekete
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-09-01
Series:Frontiers in Neurology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fneur.2021.729961/full
id doaj-88c0251dc8874fbba116741acaef33a6
record_format Article
spelling doaj-88c0251dc8874fbba116741acaef33a62021-09-10T05:34:36ZengFrontiers Media S.A.Frontiers in Neurology1664-22952021-09-011210.3389/fneur.2021.729961729961Intestinal Decontamination Therapy for Dyskinesia and Motor Fluctuations in Parkinson's DiseaseJosé Fidel Baizabal-Carvallo0Marlene Alonso-Juarez1Robert Fekete2Department of Sciences and Engineering, University of Guanajuato, León, MexicoDepartment of Medicine, National Polytechnic Institute, México City, MexicoDepartment of Neurology, New York Medical College, Valhalla, NY, United StatesParkinson's disease is neurodegenerative disorder with an initial robust response to levodopa. As the disease progresses, patients frequently develop dyskinesia and motor fluctuations, which are sometimes resistant to pharmacological therapy. In recent years, abnormalities in gut microbiota have been identified in these patients with a possible role in motor manifestations. Dysbiosis may reduce levodopa absorption leading to delayed “On” or “no-On” states. Among 84 consecutive patients with PD, we selected 14 with levodopa-induced dyskinesia and motor fluctuations with a Movement Disorders Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part IV ≥ 8 points following a trial of pharmacological adjustment 2–3 months prior to study enrollment or adjustments in deep brain stimulation therapy. Patients received treatment with sodium phosphate enema followed by oral rifaximin and polyethylene glycol for 7 and 10 days, respectively. Evaluations between 14 to 21 days after starting treatment showed improvement in MDS-UPDRS-IV (P = 0.001), including duration (P = 0.001) and severity of dyskinesia (P = 0.003); duration of medication “Off”-state (P = 0.004); functional impact of motor fluctuations (P = 0.047) and complexity of motor fluctuations (P = 0.031); no statistical improvement was observed in “Off” dystonia (P = 0.109) and total motor scores (P = 0.430). Marked to moderate improvement in dyskinesia was observed in 57% of cases with blinded evaluation of videos. About 80% of patients perceived moderate to robust improvement at follow-up. A therapeutic strategy aimed at decontamination of intestines showed benefit in motor fluctuations and dyskinesia. Further studies should confirm and clarify the mechanism of improvement observed in these patients.https://www.frontiersin.org/articles/10.3389/fneur.2021.729961/fullparkinsonismmicrobiotaParkinson's diseasedysbiosistreatmentdyskinesia
collection DOAJ
language English
format Article
sources DOAJ
author José Fidel Baizabal-Carvallo
Marlene Alonso-Juarez
Robert Fekete
spellingShingle José Fidel Baizabal-Carvallo
Marlene Alonso-Juarez
Robert Fekete
Intestinal Decontamination Therapy for Dyskinesia and Motor Fluctuations in Parkinson's Disease
Frontiers in Neurology
parkinsonism
microbiota
Parkinson's disease
dysbiosis
treatment
dyskinesia
author_facet José Fidel Baizabal-Carvallo
Marlene Alonso-Juarez
Robert Fekete
author_sort José Fidel Baizabal-Carvallo
title Intestinal Decontamination Therapy for Dyskinesia and Motor Fluctuations in Parkinson's Disease
title_short Intestinal Decontamination Therapy for Dyskinesia and Motor Fluctuations in Parkinson's Disease
title_full Intestinal Decontamination Therapy for Dyskinesia and Motor Fluctuations in Parkinson's Disease
title_fullStr Intestinal Decontamination Therapy for Dyskinesia and Motor Fluctuations in Parkinson's Disease
title_full_unstemmed Intestinal Decontamination Therapy for Dyskinesia and Motor Fluctuations in Parkinson's Disease
title_sort intestinal decontamination therapy for dyskinesia and motor fluctuations in parkinson's disease
publisher Frontiers Media S.A.
series Frontiers in Neurology
issn 1664-2295
publishDate 2021-09-01
description Parkinson's disease is neurodegenerative disorder with an initial robust response to levodopa. As the disease progresses, patients frequently develop dyskinesia and motor fluctuations, which are sometimes resistant to pharmacological therapy. In recent years, abnormalities in gut microbiota have been identified in these patients with a possible role in motor manifestations. Dysbiosis may reduce levodopa absorption leading to delayed “On” or “no-On” states. Among 84 consecutive patients with PD, we selected 14 with levodopa-induced dyskinesia and motor fluctuations with a Movement Disorders Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part IV ≥ 8 points following a trial of pharmacological adjustment 2–3 months prior to study enrollment or adjustments in deep brain stimulation therapy. Patients received treatment with sodium phosphate enema followed by oral rifaximin and polyethylene glycol for 7 and 10 days, respectively. Evaluations between 14 to 21 days after starting treatment showed improvement in MDS-UPDRS-IV (P = 0.001), including duration (P = 0.001) and severity of dyskinesia (P = 0.003); duration of medication “Off”-state (P = 0.004); functional impact of motor fluctuations (P = 0.047) and complexity of motor fluctuations (P = 0.031); no statistical improvement was observed in “Off” dystonia (P = 0.109) and total motor scores (P = 0.430). Marked to moderate improvement in dyskinesia was observed in 57% of cases with blinded evaluation of videos. About 80% of patients perceived moderate to robust improvement at follow-up. A therapeutic strategy aimed at decontamination of intestines showed benefit in motor fluctuations and dyskinesia. Further studies should confirm and clarify the mechanism of improvement observed in these patients.
topic parkinsonism
microbiota
Parkinson's disease
dysbiosis
treatment
dyskinesia
url https://www.frontiersin.org/articles/10.3389/fneur.2021.729961/full
work_keys_str_mv AT josefidelbaizabalcarvallo intestinaldecontaminationtherapyfordyskinesiaandmotorfluctuationsinparkinsonsdisease
AT marlenealonsojuarez intestinaldecontaminationtherapyfordyskinesiaandmotorfluctuationsinparkinsonsdisease
AT robertfekete intestinaldecontaminationtherapyfordyskinesiaandmotorfluctuationsinparkinsonsdisease
_version_ 1717758625432207360